Fact CheckerSign in

NCT06245616Active, not recruiting

Attenuation of Postprandial Inflammatory Processes in Alzheimer's Disease Patients by Consumption of Pomace Oil

Source: ClinicalTrials.gov · Last updated 12 Feb 2026

Brief summary (registry, in English)

This research project is based on previous studies suggesting that certain components of olive pomace oil can reduce inflammation in the brain associated with neurodegenerative diseases like Alzheimer\'s. The current hypothesis proposes that particles carrying dietary fats can trigger inflammation, but if they contain bioactive compounds from olive pomace oil, this inflammatory activity will be reduced. The study aims to recruit 40 adult volunteers, both men and women, diagnosed with early-stage Alzheimer\'s. Participants will be divided into two groups based on their blood triglyceride levels. Additionally, 40 healthy individuals with similar ages will be recruited and divided into two groups based on their triglyceride levels. Recruitment will take place at the Neurology Department of Virgen de Valme University Hospital in Dos Hermanas, Sevilla. Participants must have a mild stage of Alzheimer\'s, allowing intervention through diet for prevention or slowing down disease progression. Inclusion criteria include good visual and auditory capabilities, disease monitoring by healthcare professionals, and voluntary written consent approved by the hospital\'s ethics committee. Exclusion criteria involve current medical conditions, medication use (except contraceptives), pregnancy or lactation, systemic diseases, cardiovascular events in the last two years, uncontrolled hypertension in the last six months, cancer in the last five years, recent participation in clinical trials, physical or intellectual limitations, and any connection with the study staff. Participation is voluntary, and participants can withdraw at any time without consequences. The study could benefit Alzheimer\'s patients by reducing brain inflammation and oxidative stress. For healthcare institutions, it may improve care quality and contribute to prevention and treatment policies. Scientifically, it could provide insights into the effects of compounds on Alzheimer\'s patients, potentially leading to new treatment strategies. Olive pomace oil producers may benefit from supporting the oil\'s marketing and usage with health-related information. Overall, the project aims to impact society positively by enhancing disease prevention and treatment. Regarding risks, the study involves minimal blood extraction, posing no significant threat. Participants may experience slight discomfort due to the catheter during the six-hour study period. Follow-up contact may be necessary, but participants have the right to refuse. The study will take place at Virgen de Valme University Hospital (Seville), ensuring immediate attention in case of unexpected issues. A qualified nurse, supervised by a doctor, will conduct the procedures. The study is covered by liability insurance to compensate for any health-related issues or injuries during participation. Two postprandial experiments will be conducted, administering olive pomace oil in one and high-oleic sunflower oil in the other. Blood extractions will occur before and hourly for six hours after participants consume a meal containing the respective oils, accompanied by bread and milk. The food poses no health risks. The blood extraction process involves a simple puncture with inherent risks of any standard blood withdrawal procedure. The participant has the right to clarify any doubts he/she may have at any time and to request more detailed information about the research. To do so, the participant can contact the researchers, whose contact details are at the beginning of this document. If the participant considers that all doubts have been clarified and that he/she is convinced that the he/she wants to participate in this study, he/she can then sign the informed consent form.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
80 (estimated)
First submitted
24 Jan 2024
Start date
1 May 2024
Primary completion date
30 May 2026
Lead sponsor
Spanish National Research Council
NCT number
NCT06245616

What you commit to

  • Study type: Interventional
  • Planned participants: 80
  • From 1 May 2024 to the primary completion date, 30 May 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Drug or alcohol abuse within the last 2 years.

Other illness

  • Clinically significant psychiatric disorders.
  • Systemic disease or infection that could affect safety.
  • Cardiovascular disease within the last 2 years.
  • Uncontrolled hypertension within the last 6 months.
  • Cancer within the last 5 years.
  • Insulin-dependent diabetes.

Who the study is looking for

  • Clinical diagnosis of Alzheimer's disease.
  • Adequate visual and hearing abilities.
  • Able to consume breakfast without help.

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hospital Virgen de Valme
Coordinator of this site? Confirm its status
SevilleSpainUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.